Lupin is currently trading at Rs. 1148.50, up by 5.65 points or 0.49% from its previous closing of Rs. 1142.85 on the BSE.
The scrip opened at Rs. 1165.75 and has touched a high and low of Rs. 1174.85 and Rs. 1144.50 respectively. So far 80181 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1750.00 on 29-Jul-2016 and a 52 week low of Rs. 1036.80 on 05-Jul-2017.
Last one week high and low of the scrip stood at Rs. 1176.00 and Rs. 1133.15 respectively. The current market cap of the company is Rs. 51858.39 crore.
The promoters holding in the company stood at 46.70%, while Institutions and Non-Institutions held 40.66% and 12.63% respectively.
Lupin has received final approval for its Fluocinonide Topical Solution USP, 0.05% from the United States Food and Drug Administration (USFDA) to market a generic version of County Line Pharmaceuticals, LLC’s Fluocinonide Topical Solution USP, 0.05%. Fluocinonide Topical Solution USP, 0.05% had US sales of $32.4 million, as per IMS MAT March 2017.
Lupin’s Fluocinonide Topical Solution USP, 0.05% is AT rated generic equivalent of County Line Pharmaceuticals, LLC’s Fluocinonide Topical Solution USP, 0.05%. It is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.
